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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) often persists into adulthood.
This study was designed to estimate the prevalence of ADHD in adult psychiatric outpatients in several European
countries.
Method: ADHD diagnosis was made using the Diagnostic Interview for ADHD in Adults, version 2.0 (DIVA), according
to criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and 5th
Edition (DSM-5).
Results: Of 5662 patients present/approached, 2284 (40.3 %) consented, of whom 1986 patients (87.0 %) completed
the study. Based on the DIVA, and applying DSM-IV-TR or DSM-5 criteria, 15.8 % (95 % confidence interval [CI]
14.2 %-17.4 %) or 17.4 % (95 % CI 15.7 %-19.0 %) of patients were diagnosed with ADHD, respectively. The
prevalence of ADHD was 15.3 % when counting as non-ADHD those patients who screened positive but did
not complete the DIVA (DSM-5).
Conclusions: Estimates from this study indicate that a relevant part of the psychiatric outpatient care population
suffers from ADHD.
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Background
There is growing recognition that undiagnosed and un-
treated attention-deficit/hyperactivity disorder (ADHD)
can result in multiple negative consequences for the
individual’s life as well as for society. Adults with ADHD
tend to suffer from major socioeconomic disadvantage
[1], functional impairment [2], and a diminished quality
of life [3–5]. Lower levels of education, higher levels of
unemployment, and substance use, are known to be sig-
nificantly associated with ADHD in adults [6]. Accidents
[7], early parenthood [8], and difficulties in governing
financial issues [9] are thought to be more prevalent in
adults with ADHD than in the general population.
ADHD is much more prevalent in the prison population
compared with nondelinquent controls [10, 11]. Among
patients with ADHD, the rate of criminality is lower
when they are receiving ADHD medication [12].
ADHD is also associated with a number of comorbid
psychiatric disorders, such as mood, anxiety, and sub-
stance use disorders [13]. Knowing the prevalence of
ADHD in adult outpatient psychiatric care could help
clinicians take this treatable disorder into consideration
when evaluating their patients, enabling them to target
both ADHD and comorbid condition (s), and also to
consider ADHD as a possible differential diagnosis.
There are a number of studies available regarding the
prevalence of ADHD in the general population. For
example, a meta-analysis by Simon and colleagues [14]
determined the pooled prevalence of adults with ADHD
to be 2.5 % (95 % CI, 2.1 %-3.1 %). Slightly higher estimates
of 3.4 % [13] and 4.4 % [15] have also been proposed.
Prevalence of ADHD is expected to be higher in the
psychiatric outpatient population than in the general
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population, but only a few estimates are available.
Almeida Montes and colleagues [16] found in a psychi-
atric nonpsychotic outpatient sample in Mexico a preva-
lence of 16.8 %. Similarly, Rao and Place [17] estimated
the frequency of undiagnosed ADHD in 4 general adult
psychiatry outpatient clinics in North East England to be
22 %. Therefore, to contribute to a better understanding
of the pattern of clinical presentation of ADHD in adult
mental health care, the primary objective of this study was
to estimate the prevalence of ADHD in adult outpatient
psychiatric care in several European countries. Secondary
objectives of this study were to 1) characterize the adult
ADHD population in terms of symptoms, functioning,
quality of life, work status, resource use and comorbid
conditions, and 2) to examine the effect of differences
between Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition, Text Revision (DSM-IV-TR) [18]
and 5th Edition (DSM-5) [19] criteria for ADHD.
Methods
Site selection and patients
This was a multinational study conducted in Austria,
Belgium, Denmark, Germany, The Netherlands, Spain,
Sweden, and the United Kingdom. The study aim was to
reflect the situation and presence of adult patients with
ADHD in the psychiatric outpatient health care system
in each country or a pool/group of countries with a
similar mental health care organization. Therefore, the
study was not conducted at specialized ADHD centres,
but at sites providing general psychiatric care to a popu-
lation as unselected as possible in the respective health
care system. Four types of sites were defined to achieve
this goal: general psychiatry outpatient clinics linked to
general hospitals, private psychiatric practices, commu-
nity mental health centres, and outpatient clinics of psy-
chiatric hospitals. The distribution of sites was intended
to reflect the different levels and various settings of out-
patient mental health care in each participating country
and to examine a representative population of adults
using outpatient psychiatric care. However, for some
countries, because of the limited number of sites able to
participate, the results might not be as representative as
intended.
At each study site, all patients, regardless of their
existing diagnoses (including ADHD), were invited to
participate in the study. The sites were asked to
approach all patients during their normal clinic days
during prespecified times and days of the week until
their predefined number of entered patients per week
was reached. These prespecified inclusion periods varied
over the course of the study to cover all working days
and times (to ensure that a representative population of
that specific facility was included). Inclusion criteria were
1) males or females attending psychiatric outpatient care,
ages 18 to 65 years; and 2) having signed an informed con-
sent to release information prior to any procedure. Exclu-
sion criteria were 1) mental disability or disease state to an
extent that prevents the patient from understanding the
nature of the study or that prevents the patient from reli-
ably following procedures; and 2) psychotic disorder at
presentation or from patient’s history (schizophrenia,
schizo-affective, schizophreniform, delusional disorder),
however, treatment with antipsychotics for other indica-
tions was not an exclusion criterion.
This study was submitted to ethical review boards
(ERBs) for approval whenever required by local law. In
addition, regardless of local law, this study was submit-
ted to at least one independent body (for example, ERB)
per country for review and to confirm that the study was
considered noninterventional in that country. Regulatory
authorities were notified and approval sought as required
by local laws and regulations. Progress reports were
submitted to ERBs and regulatory authorities as required
by local laws and regulations. This study was conducted in
accordance with the ethical principles that have their
origin in the Declaration of Helsinki and that are
consistent with good clinical practice (GCP) and applic-
able laws and regulations of the countries where the study
was conducted.
Study design, procedures, and scales
After having provided their informed consent for the
release of their anonymized data, patients were assessed
clinically, using solicited questions and diagnostic instru-
ments (self–and physician-rated scales). Screening proce-
dures closely followed the guidance given in the European
Consensus Statement of the European Network Adult
ADHD [20]. After collection of patient demographic infor-
mation and characteristics, patients were asked about any
previous ADHD diagnosis. Patients were also screened
with Part A of the Adult ADHD Self-Report Scale (ASRS)
[21]. (The ASRS is an instrument consisting of the 18
DSM-IV-TR criteria. Six of the 18 questions, found to be
the most predictive of ADHD, form Part A.) As the word-
ing of 4 of the items of the ASRS Part A is identical to the
4 ADHD items in the Provisional Diagnostic Instrument-4
(PDI-4) [22], responses on these items were used to derive
a score for the PDI-4 as well.
A positive screen according to the ASRS (at least 4 out
of 6 responses exceeding threshold) or the PDI-4 ADHD
questions (at least 3 out of 4 responses exceeding
threshold), a previous ADHD diagnosis, or suspicion of
ADHD by clinical impression resulted in further assess-
ment using the Diagnostic Interview for ADHD in Adults
(DIVA) [23] according to the criteria of the DSM-IV-TR
and DSM-5. For DSM-5, the number of symptoms
required for a diagnosis of ADHD (from either the in-
attention criteria or the hyperactivity/impulsivity criteria,
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or both) has been lowered from 6 to 5. Also, ADHD
symptoms must have been present by age 12 years, com-
pared to 7 years for DSM-IV-TR. The DIVA is a DSM-
based semistructured interview covering the childhood
and adulthood DSM symptoms list for ADHD, and pro-
viding examples of impairments commonly associated
with the symptoms in 5 areas of everyday life for each age
group: work and education; relationships and family life;
social contacts; free time and hobbies; self-confidence and
self-image. Whenever possible, the DIVA was completed
with the patient in the presence of a partner/friend and/or
family member, to enable retrospective and collateral in-
formation to be ascertained at the same time. Information
received via telephone from partners/friends and/or family
members was also accepted, if available. Diagnosis of psy-
chiatric disorders other than ADHD was done according
to the usual standards of each site.
The following scales/questions were given to all
subjects, regardless of the outcome of ADHD screening.
Clinical Global Impressions-Severity (CGI-S) [24], a
clinician-rated scale ranging from 1 (not at all ill) to 7
(among the most extremely ill), was used to rate the
severity of overall mental illness at the time of study
entry. Information about clinical status (other than
ADHD) and medical history (guided by DSM-IV-TR or
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision, whichever is
used routinely at that site) was collected along with family
history. Information on functioning was collected using
the Sheehan Disability Scale (SDS) [25] as well as other
questions to the patient. The SDS was used to assess
changes in patients’ personal work schedules, social
life/leisure activities, and family life/home responsibilities.
Responses for each item range from 0 to 10 (higher values
indicate greater disruption). The SDS also asks for the
number of days lost and unproductive days in the last
week. Information on the patients’ quality of life (QoL)
and resource utilization was collected by the use of
EuroQol-5 Dimensions (EQ-5D) [26] as well as direct
questions to the patient. The EQ-5D assesses a patient’s
current, perceived, health-related quality of life by asking
the patient to rate their impairment as low, medium, or
high. The EuroQol Visual Analog Scale (EQ VAS) assesses
the respondent’s self-rated overall health status on the day
of completion (0 = lowest possible to 100 = highest
possible).
In addition, patients were asked questions covering
known ADHD related aspects concerning general health
and conduct of life.
Statistical analysis
Since the analyses were largely descriptive and explora-
tory, p-values were not calculated. Confidence intervals
(95 % level, 2-sided, computed using the normal
approximation) were used as descriptive measures only
and were not meant to support statistical inferences. No
correction for multiplicity was done.
The prevalence of ADHD in outpatient psychiatric
care was estimated using the DIVA. The denominator
comprised all patients who completed the screening in-
strument, excluding any who had a positive screen but
were not assessed using the DIVA. A sensitivity analysis
was also completed to assess the effect of excluding
these patients.
The association of ADHD diagnosis with a subset of
endpoints was analyzed using regression models (either
logistic regression or analysis of covariance, as appropri-
ate), adjusting for age, gender, and country.
Results
Patient disposition and characteristics
Of 5662 outpatients present at sites during the study
and approached, 2284 (40.3 %) were included. Reasons
for ineligibility in the study are listed in Fig. 1. Patients
were 17 to 72 (median = 42) years of age, and 58.8 %
were women. Of the 2284 patients included in the study,
1079 (47.2 %) screened positive for ADHD. Table 1 pro-
vides the number of the patients fulfilling the various
ADHD screening criteria and the percentages of patients
eventually diagnosed with ADHD according to the DIVA.
Prevalence of ADHD in adults
Based on the DIVA (using DSM-IV-TR criteria), 15.8 %
(318/2009, 95 % confidence interval [CI] 14.2 %-17.4 %)
of all participating patients suffered from ADHD
(Table 2). The majority of these patients exhibited the
combined type (63.2 %); 29.6 % were of the inattentive
type, and 7.2 % were of the hyperactive-impulsive type.
Reducing the required number of symptoms in child-
hood from 6 to 5 resulted in an increase in prevalence
to 19.9 %; this is in fact close to the clinical judgment
(last DIVA item: “Diagnosis ADHD yes/no”) of 22.6 %.
When DSM-5 criteria were applied to patient responses
on the DIVA, the prevalence of ADHD was 17.4 % (349/
2009; 95 % CI, 15.7 %-19.0 %). The prevalence of ADHD
was 15.3 % (349/2274; 95 % CI, 13.9 %-16.8 %) when
counting as non-ADHD those patients who screened
positive but did not complete the DIVA (sensitivity
analysis). All statistics presented going forward will be
based on DSM-5 criteria.
Outpatients with ADHD were younger compared to
patients without ADHD for both males (median 32 versus
45 years old) and females (median 34 versus 43 years old).
Of the 349 patients who were diagnosed with ADHD
using the DIVA, 53.9 % had not been previously diagnosed
with ADHD. Most of the patients who were diagnosed
with ADHD with the DIVA had not been treated for
ADHD in childhood (93.1 %), adolescence (90.8 %), or
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adulthood (67.3 %). Among patients with a known ADHD
diagnosis prior to the study, average age at diagnosis was
28.1 (standard deviation 13.62) years.
Considerable variability in ADHD rates was associated
with country (range: 9.0 % to 30.8 %) (Fig. 2). This variabil-
ity was also evident when countries were pooled by region:
Austria/Belgium/Germany (12.3 % [95 % CI, 9.9 %-14.6 %]);
Spain (14.1 % [95 % CI, 11.4 %-16.7 %]); United Kingdom
(22.4 % [95 % CI, 17.5 %-27.2 %]); and Denmark/Sweden/
The Netherlands (30.7 % [95 % CI, 25.8 %-35.7 %]). Differ-
ences in ADHD rates were also found between outpatient
settings: general psychiatry outpatient clinics linked to gen-
eral hospitals (11.7 % [95 % CI, 8.5 %-14.9 %]), private psy-
chiatric practices (18.0 % [95 % CI, 15.7 %-20.4 %]),
community mental health centres (22.1 % [95 % CI, 18.0 %-
26.2 %]), and outpatient clinics of psychiatric hospitals
(15.8 % [95 % CI, 10.9 %-20.7 %]). Rates of exclusion also
varied considerably by country. The lowest exclusion rates
were in Swedish (0 %; ADHD prevalence 30.0 %) and in
Belgium (17.2 %; ADHD prevalence 12.2 %); the highest ex-
clusion rates were in Austria (77.4 %; ADHD prevalence
9 %) and Germany (71.3 %; ADHD prevalence 14.2 %).
The prevalence of ADHD in women was less than in
men (14.4 % [95 % CI, 12.4 %-16.4 %] versus 21.6 %
[95 % CI, 18.8 %-24.4 %]). However, a greater percentage
of women than men were diagnosed with ADHD for the
first time during the study (60.4 % versus 47.8 %).
Patients with ADHD were more likely to have a first-
degree relative diagnosed with ADHD than patients
without ADHD (14.9 % versus 3.7 %).
Psychiatric diagnoses and neurological symptoms
The most common type of comorbid psychiatric disorder
among patients with ADHD was depression. Within the
Unable to participate = 3378 (59.7%)
904 (26.8%) Personal reasons
711 (21.0%) Practical reasons
1763 (52.2%) Criteria not met 
Age (n=468)
Informed consent not signed (n=21)









Screened positive but did not undergo DIVA questionnaire (n=188) b
a 2274 patients completed screening.
b 265 patients screened positive, but did not undergo the DIVA. Of these, 188 patients were listed as 
“completed” by the investigator.
5662 Patients present/approached 
2284 Patients included in study a
1986 Patients completed
Fig. 1 Patient disposition. Abbreviations: DIVA = Diagnostic Interview for ADHD in Adults; n = number of affected patients
Table 1 Screening Criteria Versus DIVA Completion
Criteria Positive Screen Screened Positive But Did Not Complete the DIVA ADHD Established by the DIVA
(N = 1079) (N = 265) (N = 349)
ASRS 941 (87.2) 244 (25.9)a 313 (89.7)
PDI-4 433 (40.1) 74 (17.1)a 195 (55.9)
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; ASRS = Adult ADHD Self-Report Scale, DIVA; DIVA = Diagnostic Interview for ADHD in Adults;
N = number of patients; PDI-4 = Provisional Diagnostic Instrument-4
aPercentage of patients who screened positive but did not receive the DIVA
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ADHD group, depression was more commonly diagnosed
among patients who were diagnosed with ADHD during
the study (48.9 % [95 % CI, 41.8 %-56.1 %]) than among
patients whose ADHD was known prior to the study
(ADHD treated: 36.0 % [95 % CI, 27.2 %-44.8 %]; ADHD
untreated: 36.2 % [95 % CI, 22.4 %-49.9 %]). Anxiety dis-
order was also common among ADHD and non-ADHD
patients (Table 3). Anxiety disorders tended to be less
prevalent among patients who had ADHD that was
previously identified and treated (28.1 % [95 % CI,
19.8 %-36.3 %]) compared to those patients with
previously identified but untreated ADHD (44.7 %
[95 % CI, 30.5 %-58.9 %]). Patients with ADHD, as
compared to patients without ADHD, were more
Table 2 Prevalence of ADHD According to the DIVA Using DSM-IV-TR and DSM-5 Criteria
Eligible Patients (N = 2284)
n (%)
Patients completing screening 2274/2284 (99.6)a
Positive screen for ADHD 1079/2274 (47.4)
Negative screen for ADHD 1195/2274 (52.6)
Patients completing DIVA 814/1079 (75.4)b
DSM-IV-TR Criteria DSM-5 Criteria
n (%) n (%)
N = 2284c N = 2284c
Diagnosed with ADHD based on DIVA 318 (15.8) 349 (17.4)
95 % CI 14.2-17.4 15.7-19.0
Diagnosis by category
Combined 201 (10.0) 256 (12.7)
Inattentive 94 (4.7) 78 (3.9)
Hyperactive/impulsive 23 (1.1) 15 (0.7)
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; CI = confidence interval; DIVA = Diagnostic Interview for ADHD in Adults; DSM = Diagnostic and
Statistical Manual of Mental Disorders; IV = 4th Edition; N = number of patients; n = number of affected patients
a10 patients who entered the study discontinued before completing the screening procedure
b265 patients who screened positive were not given the DIVA
cThe calculation of prevalence was based on 2009 patients (2284 patients minus 10 patients who did not complete the screening, and 265 patients who screened
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N=2284
Fig. 2 ADHD prevalence in nonpsychotic psychiatric outpatients as determined by the DIVA according to criteria of the DSM-5, by country and
setting. Abbreviations: ADHD = attention-deficit/hyperactivity disorder; CI = confidence interval; DIVA = Diagnostic Interview for ADHD in Adults;
DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; N = number of patients; S1 = general psychiatry outpatient clinics
linked to general hospitals; S2 = private psychiatric practices; S3 = community mental health centers; S4 = outpatient clinics of psychiatric hospitals;
UK = United Kingdom
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likely to present with substance use/dependence
(Table 3). Interestingly, substance use was less com-
mon among patients with newly diagnosed ADHD
(4.8 % [95 % CI, 1.7 %-7.8 %]) compared with patients
previously treated for ADHD (14.9 % [95 % CI,
8.4 %-21.5 %]).
Table 3 also summarises the percentages of patients
with various disorders who also had ADHD. A diagnosis
of ADHD was very common among patients presenting
with substance abuse (30.8 % [95 % CI, 21.9 %-39.6 %]),
substance dependence (24.4 % [95 % CI, 15.3 %-33.5 %]),
and alcohol abuse (27.1 % [95 % CI, 19.5 %-34.6 %]).
Only 11.5 % [95 % CI, 8.1 %-14.8 %] of ADHD patients
in the psychiatric outpatient settings were not diagnosed
with any additional psychiatric diagnosis, an indication
of the generally high disease burden in this condition.
For those patients previously treated for ADHD, 18.4 %
[95 % CI, 11.3 %-25.5 %] had no other psychiatric diagno-
sis; for patients with previously-identified but untreated
ADHD, 23.4 % [95 % CI, 11.3 %-35.5 %] had no other
psychiatric diagnosis.
Overall, neurological symptoms/diagnoses were rare
and were not more common in patients with ADHD
than without ADHD with only minor differences between
groups in the percentage of patients with tics, Tourette’s
syndrome, coordination deficiencies, or deficiencies in fine
motor skills (Table 3).
Patients with ADHD reported more tobacco use than
patients without ADHD (47.3 % [95 % CI, 42.0 %-52.5 %]
versus 36.9 % [95 % CI 34.5 %-39.2 %]) as well as
more respiratory dysfunction (12.3 % versus 6.3 %).
Diagnoses related to higher age were less common in
patients with ADHD (diabetes mellitus: 1.4 % versus
4.3 %; cardiovascular disease: 4.0 % versus 9.0 %).
Table 3 Prevalence of Neurological Symptoms/Diagnoses and Psychiatric Disorders Among Patients with ADHD
ADHD Diagnosis Established by the DIVA
Prevalence of ADHD Among
Patients with Other Disorders
Prevalence of Other Disorders
Among Patients with ADHD
Prevalence of Other Disorders
Among Non-ADHD Patients
(N = 349), (N = 349), (N = 1660),
n (%) n (%) n (%)
Psychiatric disordersa
Depression (n = 1215) 150 (12.3) 150 (43.0) 894 (53.9)
Dysthymia (n = 253) 34 (13.4) 34 (9.7) 198 (11.9)
Bipolar disorder (n = 268) 29 (10.8) 29 (8.3) 192 (11.6)
Obsessive-compulsive disorder (n= 126) 17 (13.5) 17 (4.9) 92 (5.5)
Anxiety disorders (n = 803) 127 (15.8) 127 (36.4) 575 (34.6)
Eating disorders (n = 113) 24 (21.2) 24 (6.9) 76 (4.6)
Substance abuse (n = 104) 32 (30.8) 32 (9.2) 56 (3.4)
Substance dependence (n = 86) 21 (24.4) 21 (6.0) 50 (3.0)
Alcohol dependence (n = 109) 14 (12.8) 14 (4.0) 81 (4.9)
Alcohol abuse (n = 133) 36 (27.1) 36 (10.3) 87 (5.2)
Non-substance dependence (n = 30) 4 (13.3) 4 (1.1) 20 (1.2)
Antisocial personality disorders (n = 24) 4 (16.7) 4 (1.1) 14 (0.8)
Borderline personality disorders (n= 172) 32 (18.6) 32 (9.2) 111 (6.7)
Autistic spectrum disorder (n = 36) 9 (25.0) 9 (2.6) 22 (1.3)
Other (n = 273) 56 (20.5) 56 (16.0) 184 (11.1)
No other psychiatric diagnosis (n= 115) 40 (34.8) 40 (11.5) 56 (3.4)
Neurological symptoms/diagnoses
Any present 18 (5.2) 60 (3.6)
Tic disorder 7 (2.0) 29 (1.7)
Tourette’s syndrome 3 (0.9) 15 (0.9)
Coordination deficiencies 9 (2.6) 25 (1.5)
Deficiencies in fine motor skills 8 (2.3) 41 (2.5)
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; CI = confidence interval; DIVA = Diagnostic Interview for ADHD in Adults; N = number of patients;
n = number of affected patients
aThe n’s for overall comorbidity rates in column 1 are based on all eligible patients (including those with a positive screen but no DIVA assessment) and do not
add up to n’s in columns 3 and 4
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Resource utilization (treatment)
Treatment with psychotropic non-ADHD medications is
substantial for both groups. Logistic regression analysis
indicated that patients with ADHD were less likely to be
prescribed antidepressants than patients who did not
have ADHD (Table 4). However, patients with treated
ADHD were more likely to be prescribed antipsychotic
medication (17 out of 114 treated patients versus 1 out
of 47 untreated patients).
Overall, the percentage of patients receiving psychother-
apy was similar between the ADHD and non-ADHD
groups, but the odds ratio (OR) points toward lower use
of psychotherapy for patients with ADHD (Table 4).
Patients previously diagnosed with ADHD (but untreated)
were less likely than patients without ADHD to have
received psychotherapy in the previous 6 months
(OR = 0.41 [95 % CI, 0.20-0.85]).
There was a trend toward greater use of “other”
therapy by patients with ADHD (Table 4). Also, patients
with previously diagnosed and treated ADHD were
more likely to have received other therapy than
patients with previously diagnosed but untreated ADHD
(OR = 6.74 [95 % CI, 1.96-23.18]), patients whose ADHD
was diagnosed during this study (OR = 5.11 [95 % CI,
2.58-10.13]), and patients without ADHD (OR = 4.88
[95 % CI, 3.03-7.86]).
Overall, ADHD and non-ADHD patients were similar
in the number of visits to a psychiatrist (Table 4). How-
ever, patients with previously diagnosed and treated
ADHD were more likely to have visited a psychiatrist in
the previous 6 months than patients with previously di-
agnosed but untreated ADHD (OR = 3.51 [95 % CI,
1.38-8.92), patients whose ADHD was diagnosed during
this study (OR = 2.97 [95 % CI, 1.38-6.39]), and patients
without ADHD (OR = 2.36 [95 % CI, 1.19-4.70]).
Patient disability and functioning
Patients with ADHD, as compared to patients without
ADHD, had higher CGI-S scores (mean [95 % CI] 3.8
[3.7-3.9] versus 3.3 [3.2-3.3] points) and were more likely
to be “moderately,” “markedly,” or “severely” ill (63.9 %
versus 46.7 %). Among patients with ADHD, patients
who were only diagnosed during the study were less ill
(mean [95 % CI] CGI-S = 3.6 [3.4-3.8]) than patients pre-
viously treated for ADHD (mean [95 % CI] CGI-S = 4.1
[3.9-4.3]). On the SDS (Table 5), patients with ADHD,
compared to patients without ADHD, reported more
disability in all 3 areas (work/school, social life, and fam-
ily life/home duties). Patients with ADHD also reported
more days lost at work and more underproductive days.
Among patients diagnosed with ADHD, differences in
SDS mean (95 % CI) total scores between patients only
diagnosed during this study (18.7 [17.8, 19.7]), those
previously diagnosed and treated (19.1 [17.8, 20.3]),
and those previously diagnosed but untreated (19.3
[17.4, 21.3]), were minimal. On the EQ-5D, patients
with ADHD, as compared to patients without ADHD,
reported more problems performing their usual activities
and more often reported being “extremely anxious or
depressed” (Table 5). More patients with newly diagnosed
ADHD (due to the study) reported that they were
“extremely anxious or depressed” (30.9 %) than patients
with previously diagnosed with and treated for ADHD
(15.8 %), and patients previously diagnosed with ADHD
but untreated (21.3 %).





Odds Ratio (ADHD versus
No ADHD)
(N = 349) (N = 1660) (95 % CI)
Antidepressants, n (%) 199 (57.0) 1193 (71.9) 0.66 (0.49-0.89)
Anxiolytics, sedatives, and hypnotics, n (%) 105 (30.1) 625 (37.7) 0.87 (0.61-1.24)
Antipsychotics, n (%) 59 (16.9) 308 (18.6) 0.51 (0.25-1.05)
Mood stabilizers, n (%) 38 (10.9) 235 (14.2) 0.82 (0.51-1.31)
Psychotherapy, n (%) 108 (30.9) 451 (27.2) 0.72 (0.52-1.00)
Other therapy, n (%)a 54 (15.5) 137 (8.3) 1.50 (0.91-2.49)
Visits to psychiatrist, n (%) 291 (83.4) 1387 (83.6) 1.08 (0.74-1.58)
Visits to psychotherapist, n (%) 103 (29.5) 449 (27.0) N/A
Visits to mental health worker, n (%) 62 (17.8) 181 (10.9) N/A
Visits to other, n (%) 40 (11.5) 216 (13.0) N/A
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; CI = confidence interval; DIVA = Diagnostic Interview for ADHD in Adults; N = number of patients;
n = number of affected patients; N/A = not available
a“Other therapy” refers to alternative therapeutic strategies, including osteopathy, yoga, psychoeducation, mindfulness training, etc
Note: Logistic regression was used for all binary outcomes
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Patients with ADHD, compared to patients who did
not suffer from ADHD, reported having fewer Master’s
or Bachelor’s degrees and having more often obtained
vocational training. Women with ADHD were less likely
to be employed full time than women without ADHD;
however, this effect of ADHD was absent for men. Pa-
tients with ADHD had more previous employers during
the previous 3 years and were less likely to be working
at their level of qualification. Patients with ADHD were
also less likely to be living with a partner. In our sample,
overall, patients with ADHD had fewer biological
children. However, an age-adjusted analysis indicates
that patients with ADHD had more biological children at
42 and 51 years of age. Patients with ADHD, compared to
patients who did not have ADHD, were less likely to have
a driving license at all, had their driving license revoked
more often, and had more accidents, more speeding
tickets, and more parking tickets (Table 6).
Discussion
To our knowledge, this is the first multinational, cross-
sectional study to evaluate the prevalence of ADHD in
outpatient general psychiatric care in Europe. Given the
high rate of psychiatric comorbidities in adult individuals
with ADHD [1, 2], it seems logical that many individuals
with ADHD would already have had contact with
psychiatric services and would therefore be likely to be
receiving psychiatric care in outpatient clinics. We found
the prevalence of ADHD in our sample, based on
DSM-IV-TR criteria, to be 15.8 %. However, based on
the new DSM-5 criteria, as expected, the prevalence
rate in our sample increased to 17.4 %, overall. As we
hypothesized, this value is much higher than for the
general population, for which there are several esti-
mates, including 2.5 % [14], 3.4 % [13], and 4.4 %
[15]. Our estimate agrees well with Almeida Montes
and colleagues [16]16 who found a prevalence of
16.8 % in nonpsychotic outpatients. However, they
found the rate of ADHD was more than twice as high
for women than for men (21.6 % versus 8.5 %), the
reverse of what we found. (It should be noted, however,
that a higher proportion of women were newly diagnosed
with ADHD in the present study.) Rao and Place [17]
reported that 22 % of their sample from outpatient clinics
in North East England could be diagnosed with ADHD,
which is higher than our overall prevalence estimate but
in good agreement with our estimate for psychiatric
outpatients in the United Kingdom (22.4 %).
We found that the most common subtype of ADHD
in our sample was the combined subtype (63.2 %).
However, a recent meta-analytic review found that
the most common form of ADHD in the general
adult population is the inattentive type [27]. It is
possible that the combined subtype only appears to
be more prevalent because treatment is more often
sought for these patients. Alternatively, the combined
subtype may carry a greater risk for psychiatric
comorbidity [28].
Table 5 SDS and EuroQoL-5 Dimensions Scores, by ADHD Diagnosis
N ADHD Diagnosis Established by the DIVA (DSM-5) N ADHD Diagnosis Not Established
(N = 349) (N = 1660)
SDS
Total score, mean (SD) 348 18.9 (6.61) 1659 11.6 (8.55)
Work/school, mean (SD) 327 6.5 (2.62) 1466 4.1 (3.25)
Social life, mean (SD) 348 6.1 (2.68) 1659 3.8 (3.13)
Family life/home duties, mean (SD) 348 6.3 (2.61) 1659 3.8 (3.08)
Days lost, mean (SD) 348 1.9 (2.39) 1659 1.2 (2.14)
Underproductive days, mean (SD) 348 3.3 (2.46) 1659 2.0 (2.38)
EQ-5D
Problems with mobility, n (%) 349 52 (14.9) 1660 285 (17.2)
Problems with self-care, n (%) 349 50 (14.3) 1660 141 (8.5)
Problems performing usual activities, n (%) 349 231 (66.2) 1660 684 (41.2)
Moderate/extreme pain or discomfort, n (%) 349 164 (47.0) 1660 790 (47.6)
Moderately/extremely anxious or depressed, n (%) 349 268 (76.8) 1660 1157 (69.7)
Visual analogue scale, mean (SD) 348 62.0 (22.86) 1659 64.3 (21.65)
Health state value, mean (SD) 348 0.609 (0.332) 1659 0.687 (0.292)
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; DIVA = Diagnostic Interview for ADHD in Adults; DSM =Diagnostic and Statistical Manual of Mental
Disorders; EQ-5D = EuroQoL-5 Dimension; N = number of patients; n = number of affected patients; SD = standard deviation; SDS = Sheehan Disability Scale
Deberdt et al. BMC Psychiatry  (2015) 15:242 Page 8 of 13
Overall, we noted considerable variability in prevalence
of ADHD associated with country, possibly reflecting dif-
ferences in the referral selection process in their respective
health care systems.
But what is even more relevant to patients, their treating
mental health professionals, and the respective national
health care system, is the impact of ADHD, in terms of
well-being, functioning, and impairment. We found that,
compared with patients who did not have ADHD, patients
with ADHD had higher CGI-S scores (were more ill),
which is an indicator of functional disability, as well. This
observation was affirmed in that they reported more prob-
lems performing their usual activities on the EQ-5D, and
more disability overall. The SDS results indicate that, on
average, patients with ADHD have moderate to severe
impairments in work, family, and social functioning, while
the impairment of the other outpatients without ADHD is
between mild and moderate. The high level of impairment
may be related to the fact that ADHD is causing a chronic
impairment in multiple domains, in contrast to episodic
impairment in depression and impairment limited to one
or a few domains as is usually the case with anxiety
disorders [18]. In addition, the fact that ADHD starts
in childhood and can lead to multiple occurrences of
failure and social distress could give reason to the
observed developments.
In agreement with previous studies from various
geographic areas [6, 13, 29–31], we found that outpatients
with ADHD were more likely to report substance abuse/
dependence than patients who did not have ADHD. A
Table 6 Assessment of Functioning






(N = 349) (N = 1660) (95 % CI)
Master’s/Bachelor’s degrees, n (%) 68 (19.4) 399 (24.0)
ADHD, versus non-ADHD, OR (95 % CI) 0.60 (0.44-0.82)
Vocational training, n (%) 88 (25.2) 293 (17.7) N/A
Total amount of formal instruction, years (SD) 346 12.58 (5.049) 1659 12.60 (4.586) N/A
Student, n (%) 52 (14.9) 90 (5.4) N/A
Employed full time, n (%) 106 (30.4) 580 (34.9)
ADHD, versus non-ADHD (female), OR (95 % CI) 0.54 (0.36-0.81)
ADHD, versus non-ADHD (male), OR (95 % CI) 0.89 (0.62-1.26)
Number of different employers in last 3 years, mean (SD) 347 1.20 (1.598) 1659 0.90 (0.936) N/A
Working at level of qualification, n (%) 159 (45.6) 840 (50.6) N/A
Number of biological children, mean (SD) 348 0.93 (1.230) 1655 1.13 (1.135)
ADHD versus non-ADHD (at age 31), LS Mean difference 0.10 (−0.03-0.23)
ADHD, yes versus non-ADHD (at age 42), LS Mean difference 0.20 (0.07-0.33)
ADHD, yes versus non-ADHD (at age 51), LS Mean difference 0.28 (0.10-0.47)
Age when first biological child was born (years), mean (SD) 159 25.50 (5.685) 998 26.70 (5.574) N/A
Age when first biological child was born (<18 years), n (%) 7 (2.0) 23 (1.4) N/A
Living with parents, n (%) 78 (22.3) 215 (13.0)
ADHD versus non-ADHD, OR (95 % CI) 1.09 (0.76-1.57)
Driving license held, n (%) 239 (68.5) 1303 (78.5) N/A
Number of times license revoked in last 3 years, mean (SD) 239 0.07 (0.303) 1300 0.04 (0.222) N/A
Number of speeding tickets in last 3 years, mean (SD) 239 1.05 (2.072) 1299 0.55 (1.664) N/A
Number of parking tickets in last 3 years, mean (SD) 239 1.12 (3.299) 1296 0.60 (1.818) N/A
Number of car accidents in last 3 years, mean (SD) 239 0.31 (0.808) 1301 0.16 (0.555) N/A
Frequency of debt, n (%) 124 (35.5) 404 (24.3) N/A
Prosecuted since adulthood, n (%) 48 (13.8) 102 (6.1) N/A
Current tobacco use, n (%) 165 (47.3) 612 (36.9) N/A
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; DIVA = Diagnostic Interview for ADHD in Adults; N = number of patients; n = number of affected
patients; SD = standard deviation
Note: Logistic regression was used for all binary outcomes; number of biological children was analyzed using analysis of covariance
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recent meta-analysis found that the prevalence of ADHD
in patients with substance use disorder was much higher
(23.1 %) than in the general population [30]. It has also
been reported that people with ADHD are more likely to
have a substance use disorder than control patients with-
out neuropsychiatric conditions [29, 31]. Importantly,
there is evidence that the risk of substance use disorder is
reduced as a result of ADHD treatment [32]. Previous
studies have also shown that ADHD is often associated
with a number of comorbid psychiatric disorders, such as
mood and anxiety disorders or substance use disorders
[13]. We found that patients who had ADHD that had
been diagnosed and treated before study entry suffered
from anxiety to a lesser degree (28.1 %) than those diag-
nosed with ADHD but untreated (44.7 %). This could be
another indicator that timely treatment of ADHD could
reduce the burden of psychiatric disease. In our sample,
88.5 % of outpatients with ADHD had at least one
additional psychiatric diagnosis.
We also found that patients with ADHD tended to
have lower academic achievement and were less likely to
be employed full time (women only), even in comparison
to patients with other psychiatric disorders. Though these
results may be partially explained by the younger age of
the patients with ADHD, we also found that those patients
were more likely to have received vocational training than
patients who did not have ADHD. These findings support
earlier work showing that adults with ADHD, compared
with controls, trended toward having lower occupational
attainment and had significantly more academic problems
in school [33].
These data are also in line with earlier reports that
adult patients with ADHD tend to have lower socioeco-
nomic status [1], more functional impairment [2, 34], and
a diminished quality of life [3–5], even more than patients
in psychiatric outpatient care. This is a compelling
argument to screen patients presenting at psychiatric
outpatient facilities for ADHD and to offer individuals
with confirmed ADHD who show impairments the
appropriate care for their ADHD symptoms in addition to
those of their comorbid diagnoses.
Finally, we found that the prevalence of ADHD was
slightly higher (17.4 % versus 15.8 %) according to DSM-5
criteria, as compared to DSM-IV-TR criteria. A similar
conclusion was made in a study of patients seeking
treatment for substance use [35]. However, this higher
prevalence was endorsed by the clinical opinion of
the participating investigators, suggesting that the
new DSM-5 criteria are matching better the clinical
assessment than the DSM-IV-TR criteria.
The prevalence of ADHD in the general psychiatric
outpatient population is so high that systematic screening
for it is recommended, especially since the symptoms and
complaints may relate to comorbid disorders so severe
that genuine ADHD symptoms are masked. However, in
this population the specificity of the common screening
tools, like the ASRS, are weak, with only half of the
patients screening positive having a confirmed diagnosis.
Therefore, a thorough diagnostic assessment of ADHD,
like we did with the DIVA instrument, is necessary.
Because such an assessment takes a considerable amount
of time (at least 1 hour per patient), it would be very
useful to look for additional screening criteria that could
improve the specificity of the existing tools with minimal
loss of sensitivity.
Limitations
First, as this was an observational study, we cannot draw
any conclusions regarding causality. We can present data
regarding how certain patient characteristics are associated
with an ADHD diagnosis, but we do not know if ADHD
caused or contributed to any of those characteristics.
Secondly, we have a substantial sample size for Europe
overall, but our ability to make comparisons between
countries is limited because of the small sample size for
some countries and because settings, which had their
own variability, were different between countries. However,
our study procedures were set up to minimize selection
effects by approaching each and every patient attending a
study facility during carefully specified times. Careful atten-
tion was given to site selection for each country with the
intention that the patients were representative. However,
for some countries, because of the limited number of sites
able to participate, the results may be less representative.
In addition, variability in training/experience in assessing
patients may have affected estimates of ADHD prevalence
in different centers and countries.
Third, other studies have shown that patients with
ADHD tend to underreport lifetime inattention problems
when giving their history and when completing scales
[36]; however, we attempted to minimize this effect by in-
cluding reports from family members. Another limitation
concerns the 265 patients who screened positive for
ADHD, but for whom the DIVA questionnaire was not
performed for various reasons. However, a sensitivity
analysis showed that this had a relatively minor impact on
the overall study.
Fourth, the high exclusion rate brings into question
the generalizability of our estimates of ADHD preva-
lence. However, there appeared to be no relationship be-
tween exclusion rates and ADHD prevalence when
measured by country.
Fifth, patients who screened negative were not further
tested using the DIVA, so we do not have an estimate of
false negatives. However, the ASRS is a very sensitive
instrument, so false negatives should have been minimal.
In addition, a positive screen on the PDI-4 ADHD ques-
tions, a previous ADHD diagnosis, or suspicion of ADHD
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by clinical impression also resulted in a positive screen,
further reducing the chances of false negatives.
Conclusions
Our findings indicate that ADHD is present in a substantial
proportion of nonpsychotic patients seeking psychiatric
help. Compared to other psychiatric outpatients, they are
among the most impaired and their medical resource needs
are comparable and in some aspects higher than in patients
without ADHD. It is hoped that data from this study
contribute to a better understanding of the presence,
the pattern of clinical presentation, and clinical picture of
patients and of implications of ADHD in adult mental
healthcare. This knowledge may be the basis for a better
allocation of appropriate diagnostic and treatment re-
sources and lead to a reduction of primary and secondary
costs due to a more focused treatment once the diagnosis
of ADHD can be properly confirmed or dismissed. Proper
application of these findings may also result in a reduced
burden to the patient due to earlier therapeutic interven-
tions and as a consequence possibly better outcomes for
patients with ADHD.
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